No Data
Poseida Therapeutics to Present New Clinical Data From Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients With Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Express News | Poseida Therapeutics Inc - Initiates P-BCMA-ALLO1 Phase 1B Clinical Trial in Patients With Multiple Myeloma, Generating $20 Mln Payment From Roche
Express News | Poseida Therapeutics to Present New Clinical Data From Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients With Relapsed/Refractory Multiple Myeloma at 21ST International Myeloma Society Annual Meeting
Poseida Therapeutics (PSTX) Gets a Buy From William Blair
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy With a T-Cell Engager in a Patient With Relapsed Multiple Myeloma
Poseida Therapeutics to Present at Upcoming Investor Conferences